510(k) Report

De Novo · Granted

Granted

Rho

DEN230023De NovoGranted Apr 9, 2024372-day reviewClass II21 CFR 892.1171

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

16 Bit, Inc. · SAO Radiology Software For Opportunistic Evaluation Of Low Bone Mineral Density

Granted on Apr 9, 2024 as a new device type through De Novo after a 372-day review. 2 later devices descend from it.

Decided
Apr 9, 2024
Review
372 days
Class
Class II
Product code
SAO
Recalls
None

2 later devices descend from it, 2 citing it directly.

Descendants, by year cleared 2025: 1 descendant cleared2026: 1 descendant cleared2020202220242026
  1. This deviceDEN230023 Rho16 Bit, Inc. · 2024
  2. Descendant · cites it directly · 0 of its ownK253192 DeepXray SpinaAlpha Intelligence Manifolds, Inc. · 2026
  3. Descendant · cites it directly · 0 of its ownK251408 OsteoSight™ Hip (v1)Naitive Technologies, Ltd. · 2025

Most influential descendants

Showing 2 of 2 · See all
  • K253192DeepXray SpinaAlpha Intelligence Manifolds, Inc. · 2026 · cites it directly0descendants
  • K251408OsteoSight™ Hip (v1)Naitive Technologies, Ltd. · 2025 · cites it directly0descendants
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
0 (this device)DEN230023Rho16 Bit, Inc.2024—
+1K253192DeepXray SpinaAlpha Intelligence Manifolds, Inc.2026—
+1K251408OsteoSight™ Hip (v1)Naitive Technologies, Ltd.2025—

Descendants by year cleared

Year clearedDevicesWith a Class I recall
202510
202610
FIG. 1 — Lineage of DEN230023, 2024–2026Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA De Novo database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in SAO? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new SAO device

  1. #1 K253192 DeepXray Spinascore 11.5 · 1 generation · no Class I recall
  2. #2 Held for the reportin the report
Get a 510(k) Report

Does it have a predicate?

De Novo decisions do not claim a predicate device.

What descends from it? (2)

2 later devices cite it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K253192DeepXray SpinaAlpha Intelligence Manifolds, Inc.20260
K251408OsteoSight™ Hip (v1)Naitive Technologies, Ltd.20250

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • Of its descendants, K253192 (Alpha Intelligence Manifolds, Inc., 2026) has gone furthest, with 0 descendants of its own.

How does its category compare?

All SAO devices

SAO Radiology Software For Opportunistic Evaluation Of Low Bone Mineral Density: FDA decisions, review times, recalls and adverse event reports over 20 years. 2024, this device’s year, is highlighted.

FDA decisions per year · SAO

1in 2025

2024: 12025: 12026 (partial year): 1
2007high 1 (2024) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · SAO

Too few SAO 510(k)s in any year since 2007 to give a median.

Recalls per year · SAO

No recall names SAO since 2007.

Adverse event reports per year · SAO

No MAUDE report names SAO since 2007.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—00
20090—00
20100—00
20110—00
20120—00
20130—00
20140—00
20150—00
20160—00
20170—00
20180—00
20190—00
20200—00
20210—00
20220—00
20230—00
20241—00
20251—00
20261—0—

What is it indicated for?

Rho is a software application intended for use opportunistically with standard frontal radiographs of the lumbar spine, thoracic spine, chest, pelvis, knee, or hand/wrist performed in patients aged 50 years and older. Rho provides a notification in the form of a report to aid radiologists and/or physician interpreters in identifying patients with possible low bone mineral density (BMD) at L1-L4 or the femoral neck to prompt a clinical assessment of bone health. Rho should not be used to rule out low BMD. Radiologists and referring clinicians should follow recommended practices for screening and assessment, regardless of the absence of Rho report.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “DEN230023: Rho.” Lineage record from FDA De Novo data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/DEN230023

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026